CD163、E-Cadherin在非小细胞肺癌肿瘤芽殖中的表达及意义  

Significance of expression of CD163 and E-Cadherin in non-small cell lung cancer tumor budding

作　　者：徐海霞[1] 邓征浩[2] 周建华[2] 林香桃 

机构地区：[1]中南大学湘雅医学院附属海口医院病理科,海南海口570208 [2]中南大学湘雅医院病理科,湖南长沙410008

出　　处：《中国热带医学》2016年第3期248-251,共4页China Tropical Medicine

基　　金：湖南省自然科学基金(No.14JJ2042)

摘　　要：目的探讨血红蛋白清道夫受体(CD163)、E钙粘附蛋白(E-Cadherin,E-Cad)在非小细胞肺癌(non-smallcell lung cancer,NSCLC)肿瘤芽殖(Tumor Budding)中的表达情况及对预后的影响。方法收集海口市人民医院手术切除经病理证实的NSCLC组织标本60例(其中鳞状细胞癌30例,肺腺癌30例),采用免疫组化法检测CD163、E-Cad在实体瘤、肿瘤芽殖(Tumor budding)及周围正常肺组织中的表达情况。结果 NSCLC肿瘤芽殖中CD163阳性率为55.0%(33/60)显著高于实体瘤的31.7%(19/60)和正常肺组织的0%(0/60),肿瘤芽殖中CD163阳性率与病理分级、淋巴结转移有关(P<0.05)。E-Cad在肿瘤芽殖中的阳性率33.3%(20/60),明显低于实体瘤的51.7%(31/60)和正常肺组织的100%(60/60)。肿瘤芽殖中E-Cad与病理分级、淋巴结转移有关(P<0.05)。结论 NSCLC肿瘤芽殖中的CD163高表达、E-Cad低表达与临床预后有一定关系。Objetive To investigate the expression of CD163 and E-Cadherin in non-small cell lung cancer（NSCLC）tumor budding, and their impact on prognosis. Methods A total of 60 surgical excision samples of NSCLC, including 30 squamous cell carcinoma and 30 adenocarcinoma, were collected after pathological confirmation in Haikou People＇s Hospital.Immunohistochemistry was used to examine the expression of CD163 and E- Cad in solid tumor, tumor budding and theadjacent normal lung tissue. Results The positive rate of CD163 in tumor budding was 55.0%（33/60） significantly higherthan in solid tumor [31.7%（19/60）] and normal lung tissue [0%（0/60）]. The positive rate of CD163 in tumor budding wascorrelated with pathological grading and lymphatic metastasis. The positive rate of E-Cad in tumor budding was 33.3%（20/60）significantly lower than in solid tumor [51.7%（31/60）] and normal lung tissue [100%（60/60）]. The positive rate of E-cad intumor budding was related to pathological grading and lymphatic metastasis（P〈0.05）. Conclusion The high expression ofCD163 and low expression of E-Cad in NSCLC may predict an unfavorable clinical outcome.

关 键 词：血红蛋白清道夫受体 E钙粘附蛋白 非小细胞肺癌 肿瘤芽殖 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]